Skip to main content
Last Updated
Case Status
In the Matter of Amgen, Inc., a corporation, and Horizon Therapeutics plc, a corporation
FTC Matter/File Number
231 0037
Docket Number
Enforcement Type
Part 3 Administrative Complaints

Case Summary

In August 2023, the FTC reached a proposed consent order with Amgen Inc. to address the potential competitive harm that would result from Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc. As part of a nationwide settlement of their challenge to the acquisition, the FTC and attorneys general from six states – California, Illinois, Minnesota, New York, Washington, and Wisconsin – also dismissed the related federal court preliminary injunction action, allowing the transaction to proceed, with the conditions imposed by the order.

Case Timeline